Concert Pharmaceuticals, Inc. Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata. The THRIVE-AA clinical program includes two international Phase 3 studies, THRIVE-AA1 and THRIVE-AA2. Enrollment in the THRIVE-AA1 trial was completed in October 2021, and topline data is expected in the second quarter of 2022.

Topline data from the THRIVE-AA2 trial is expected in the third quarter of 2022.